Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?

Surgical Endoscopy and Other Interventional Techniques

Volumn 22, Issue 5, 2008, Pages 1402-1404

  Liakakos, Theodore ^a   Roukos, Dimitrios H ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BRCA1 PROTEIN; BRCA2 PROTEIN; UVOMORULIN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL TRACT FUNCTION; HEREDITARY DIFFUSE GASTRIC CANCER SYNDROME; HOSPITAL DISCHARGE; HUMAN; INTERMETHOD COMPARISON; INTESTINE OBSTRUCTION; LAPAROSCOPIC SURGERY; LETTER; LYMPHADENECTOMY; MASTECTOMY; MOBILIZATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; SAFETY; STOMACH CANCER; SURVIVAL RATE; TREATMENT INDICATION;

CLINICAL TRIALS AS TOPIC; GASTRECTOMY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LAPAROSCOPY; QUALITY OF LIFE; RISK ASSESSMENT; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 43049130675     PISSN: 09302794     EISSN: 14322218     Source Type: Journal    
DOI: 10.1007/s00464-008-9890-3     Document Type: Letter

References (38)

1. Lee JH, Kim YW, Ryu KW (2007) A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol. Aug 20; [Epub ahead of print]
2. Shehzad K, Mohiuddin K, Nizami S et al (2007) Current status of minimal access surgery for gastric cancer. Surg Oncol 16(2):85-98. Epub 2007 Jun 7
3. Yasuda K, Shiraishi N, Etoh T, Shiromizu A, Inomata M, Kitano S (2007) Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc 21:2150-215
4. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimi-dine. N Engl J Med 357(18):1810-1820
5. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
6. Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas Couchell S (1990) A critical-evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach-an analysis of early results and long-term survival. J Cancer Res Clin 116(3):307-313
7. Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228(4):449-461
8. Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81(2):59-62
9. Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11(8):727-730
10. Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol Feb;11(2):127-129
11. Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115-125
12. Gervasoni JE, Sbayi S, Cady B (2007) Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol (in press) DOI: 10.1245/s10434-007-9360-5
13. Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98-107
14. Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanesestyle extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84(12):1602-1609
15. Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80(1):16-24
16. Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7(4):253-255
17. Roukos DH (1999) Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 6(1):46-56
18. Roukos DH, Lorenz M, Encke A (1998) Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective longterm follow-up study. Surgery 123(5):573-578
19. Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemora-diotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730
20. Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9(3):220-221
21. Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14(10):2691-2695
22. Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6(6):931-939
23. Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873-879
24. Chung DC, Yoon SS, Lauwers GY, Patel D (2007) Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med 357(3):283-291
25. Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6(3):308-312
26. Kim JJ, Song KY, Chin HM, Kim W, Jeon HM, Park CH, Park SM (2007) Totally laparoscopic gastrectomy with various types of intracorporeal anastomosis using laparoscopic linear staplers: preliminary experience. Surg Endosc Jun 26; [Epub ahead of print]
27. Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578-590
28. Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607-609
29. Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941-943
30. Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21-33
31. Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030-1034
32. Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555-1556
33. Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10(7):718-721
34. Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737-745
35. Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29-39
36. Liakakos T, Roukos DH (2008) More controversy than ever - challenges and promises towards personlized treatment of gastric cancer. Ann Surg Oncol 15(4):959-960
37. Roukos DH (2008) HER2 and response to paclitaxel in nodepositive breast cancer. N Engl J Med 358:197
38. Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139-141